|
12 Apr 2019 |
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
|
|
11 Apr 2019 |
Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
|
|
11 Apr 2019 |
Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
|
|
10 Apr 2019 |
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
|
|
09 Apr 2019 |
Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration
|
|
09 Apr 2019 |
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
|
|
09 Apr 2019 |
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
|
|
09 Apr 2019 |
PIXUVRI® (pixantrone) Receives Positive CHMP Opinion to Convert Conditional Approval into Standard Marketing Authorization in Patients with Aggressive non-Hodgkin B-cell Lymphoma
|
|
09 Apr 2019 |
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
|
|
09 Apr 2019 |
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
|
|
08 Apr 2019 |
Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
|
|
08 Apr 2019 |
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
|
|
06 Apr 2019 |
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
|
|
05 Apr 2019 |
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
|
|
05 Apr 2019 |
Nanobiotix announces first ever radioenhancer to receive European market approval
|
|
04 Apr 2019 |
EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
|
|
04 Apr 2019 |
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
|
|
03 Apr 2019 |
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
|
|
03 Apr 2019 |
Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
|
|
03 Apr 2019 |
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
|
|
03 Apr 2019 |
Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
|
|
03 Apr 2019 |
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
|
|
03 Apr 2019 |
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
|
|
02 Apr 2019 |
Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
|
|
02 Apr 2019 |
Novel First-In-Class FLIP Inhibitors for the Treatment of Cancer
|
